

Heart, Lung and Circulation (2017) xx, 1–7
 1443-9506/04/\$36.00
<http://dx.doi.org/10.1016/j.hlc.2017.03.164>

Effects of Remote Ischaemic Conditioning on Heart Rate Variability and Cardiac Function in Patients With Mild Ischaemic Heart Failure

Q1 Long Chen, PhD^{*}, Qianxing Zhou, MD, PhD, Hong Jin, PhD, Kongbo Zhu, PhD, Hong Zhi, PhD, Zhongpu Chen, PhD, Genshan Ma, MD, PhD

Q2 Department of Cardiology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China

Received 25 April 2016; received in revised form 21 January 2017; accepted 29 March 2017; online published-ahead-of-print xxx

- Q4 **Background** Cardioprotective effects of remote ischaemic conditioning (RIC) in the setting of ischaemic heart disease have been shown recently. But the effects of RIC on heart rate variability (HRV) and cardiac function in patients with stable ischaemic heart failure (IHF) are still unknown.
- Q5 **Methods** Fifty patients with stable IHF were enrolled and randomly divided into RIC group and control group. Remote ischaemic conditioning treatment was performed twice a day for six weeks. A RIC protocol consisted of 4 × 5 min inflation/deflation of the blood pressure cuff applied in the upper arm to create intermittent arm ischaemia. B-type natriuretic peptide (BNP), left ventricular ejection fraction (LVEF), 24-hour ambulatory electrocardiogram, and six-minute walk distance (6MWD) were all assessed in two groups.
- Q6 **Results** Forty-seven patients completed the study. Remote ischaemic conditioning was well-tolerated by patients in the RIC group after six weeks treatment and LVEF showed a significant increase, from 39.2% to 43.4% ($p < 0.001$), as well as decreased BNP, increased 6MWD and HRV, but this was not observed in the control group. In addition, the patients treated with RIC also showed improved NYHA class, LVEF, 6MWD, BNP level and HRV compared to control group.
- Conclusions** This study suggests that a six-week course of RIC treatment could improve cardiac function and HRV in patients with mild and stable IHF, supporting widespread use of RIC in the daily lives of these patients.
- Keywords** Remote ischaemic conditioning • Heart rate variability • Heart failure • Ischaemic heart disease

Introduction

Q7 Ischaemic heart disease is a major cause of mortality and morbidity worldwide [1]. Survival of patients with acute myocardial infarction (AMI) has largely improved in the past decades due to the advances in, and application of, modern medical therapy, percutaneous coronary intervention (PCI), and coronary artery bypass grafting (CABG). However,

the resultant ventricular dysfunction and ischaemic heart failure (IHF) have significantly increased and present, now, as a major medical problem, which substantially affects quality of life and has become a major determinant for reduced life expectancy in subjects post AMI [1]. Despite advances in drug and/or device therapy for chronic IHF with reduced left ventricular ejection fraction (LVEF), outcomes at the community level remain suboptimal [2,3]. These

Q3 ^{*}Corresponding author at: Dingjiaqiao 87, Nanjing 210009, China. Phone: +8613851638480, Fax: +862583262395, Email: longchen.crown@163.com

© 2017 Published by Elsevier B.V. on behalf of Australian and New Zealand Society of Cardiac and Thoracic Surgeons (ANZSCTS) and the Cardiac Society of Australia and New Zealand (CSANZ).

29 unsatisfactory results warrant investigation of further thera-
 30 peutic strategies to treat heart failure patients in their daily
 31 lives. A traditional way to develop new treatments is to block
 32 the mechanisms that are known to be associated with poor
 33 survival. It is now recognised that autonomic dysfunction is
 34 one such mechanism producing poor outcomes. Abnormal-
 35 ity of heart rate variability (HRV) is a way of measuring
 36 autonomic imbalance and has repeatedly been shown to
 37 be significantly associated with the degree of left ventricular
 38 dysfunction, progression, and prognosis of the patients with
 39 heart failure disease [4,5]. Medications that improve HRV are
 40 promising therapeutically as they also usually improve mor-
 41 tality [6–8].

42 Remote ischaemic conditioning (RIC), induced by repeated
 43 short-lasting ischaemia in a distant tissue – largely achieved
 44 by intermittent interruption of circulation in a limb – has
 45 recently emerged as a noninvasive and promising adjunctive
 46 therapy to avoid organ damage, thereby improving the out-
 47 comes of well-established therapies [9]. Remote ischaemic
 48 conditioning has been shown to reduce adverse left ventric-
 49 ular remodelling and improve cardiac function in rats after
 50 myocardial infarction (MI), when delivered daily for 28 days
 51 [10]. In proof-of-principle randomised clinical trials (RCTs)
 52 based on surrogate end-points such as biomarkers and imag-
 53 ing, RIC has been shown to protect against ischaemia-reper-
 54 fusion injury in the heart, brain, kidney, and lung [9].
 55 Especially, a number of clinical studies have confirmed the
 56 positive cardioprotective effects of RIC in the setting of acute
 57 myocardial injury including myocardial infarction [11], car-
 58 diac [12] and non-cardiac surgery [13] and percutaneous
 59 coronary intervention (PCI) [14]. However, the effects of
 60 RIC on stable IHF are still unclear. In addition, although
 61 the mechanisms of beneficial effects by RIC were not well
 62 established, recent data highlight that activation of auto-
 63 nomic reflex pathways contributes to powerful innate mech-
 64 anisms of cardioprotection underlying the RIC phenomena.
 65 It was reported that bilateral cervical vagotomy, surgical
 66 denervation of the ischaemic limbs by sectioning the sciatic
 67 and femoral nerves, or permanent functional depletion of
 68 sensory nerves induced by neonatal systemic capsaicin (neu-
 69 rotoxin, the active component of chilli peppers) treatment
 70 effectively abolishes RIC cardioprotection [15,16]. Therefore,
 71 we could hypothesise that RIC may bring beneficial effects to
 72 IHF by regulating cardiac autonomic function, since cardiac
 73 autonomic derangement is evident in most patients with IHF
 74 [17,18]. This study aimed to investigate the effects of six-week
 75 RIC treatment on heart rate variability and cardiac function
 76 in patients with stable IHF.

77 Methods

78 Ethics Statement

79 The protocol was approved by the ethics committee of
 80 Zhongda Hospital, Southeast University (Nanjing, China).
 81 Before entering the study, the subjects provided a full,
 82 informed, written consent.

Study Population

511 Fifty patients with stable ischaemic heart failure were
 512 recruited in this study from the outpatients in the Depart-
 513 ment of Cardiology, Zhongda Hospital, Southeast Univer-
 514 sity, Nanjing, China. Patients enrolled fulfilled the following
 515 criteria: (1) an established diagnosis of systolic heart failure
 516 for at least three months, which was based on the Framing-
 517 ham criteria [19]; (2) history of myocardial infarction or
 518 coronary artery disease confirmed by angiography; (3) LVEF
 519 <50% at transthoracic echocardiography; (4) New York
 520 Heart Association (NYHA) functional classification of I–II;
 521 (5) walking without assistance; (6) sinus rhythm without
 522 atrial fibrillation; (7) taking angiotensin converting enzyme
 523 inhibitors or angiotensin II receptor blockers and β -blocker
 524 for at least three months without dose titration unless there
 525 was a contraindication or patient was intolerant. The exclu-
 526 sion criteria were as follows: (1) more than moderate valvular
 527 heart disease; (2) recent (within six months) acute coronary
 528 syndromes; (3) history of atrial fibrillation, intermittent bun-
 529 dle branch block, or pacemaker implantation; (4) peripheral
 530 arterial disease; (5) uncontrolled hypertension (systolic blood
 531 pressure (BP) >160 mmHg or diastolic BP >100 mmHg); (6)
 532 active cancer; and (7) the presence of other serious systemic
 533 diseases.

Study Design

534 Patients included in the study were randomly divided into
 535 two groups: 1) Control group (n = 25), in which patients
 536 received standard medical therapy; 2) RIC group (n = 25),
 537 in which patients received six weeks' RIC treatment along
 538 with standard medical therapy. All heart failure medications
 539 were required to be continued in unchanged dosage for the
 540 duration of the study, and all examinations were performed
 541 before and after the six-week course of RIC treatment.

542 In each RIC treatment, a BP cuff was applied to the upper
 543 arm of each patient, first to measure BP in the left arm, then
 544 immediately thereafter the BP cuff was inflated to a pressure
 545 of 20 mmHg greater than the patient's systolic BP, it was then
 546 left inflated for five minutes, after which the cuff was
 547 deflated. Five minutes later, the cuff was inflated again as
 548 before, and a RIC-protocol was applied consisting of
 549 4 × 5 min inflation/deflation of the cuff. Remote ischaemic
 550 conditioning treatment was repeated each morning and
 551 evening by the patients themselves. A physician (CL) con-
 552 firmed that the subjects operated the RIC procedure correctly
 553 in the first week. After the first week of participation in
 554 monitored sessions, the patients performed the same proto-
 555 col for three days per week under direct supervision of the
 556 physician in the hospital as before and four days at their
 557 home.

558 Blood samples were collected in test tubes containing
 559 EDTA at baseline and after six weeks of treatment with
 560 patients in the supine position for at least 30 minutes. The
 561 plasma was separated from blood cells by centrifugation
 562 and frozen at – 80 °C. Plasma concentrations of b-type natri-
 563 uretic peptide (BNP) were measured using a specific

Download English Version:

<https://daneshyari.com/en/article/8659776>

Download Persian Version:

<https://daneshyari.com/article/8659776>

[Daneshyari.com](https://daneshyari.com)